Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Seattle Children's)
- Development stage
- Unknown
- Lead developer
- Seattle Children's
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplant is a live biotherapeutic product that was investigated by Seattle Children's Hospital for the treatment of pediatric Crohn's disease. The therapy involves the transfer of fecal matter from a healthy, screened donor into the gastrointestinal tract of a patient, which in this specific trial was done via a nasogastric tube. [4, 6] The primary mechanism of action is the restoration of a healthy gut microbiome, which is believed to correct dysbiosis (an imbalance of gut bacteria) often seen in Crohn's disease. [1, 3] By introducing a diverse and balanced microbial community, fecal microbiota transplant aims to reduce inflammation, modulate the patient's immune response, and improve clinical symptoms. [3] A double-blind, placebo-controlled clinical trial (NCT02272868) was conducted to evaluate its efficacy and safety in patients aged 12 to 21 with active Crohn's disease. [4]
- Other names
- fecal microbial transplantstool transplant
Beyond the preview
Go deeper on fecal microbiota transplant (Seattle Children's).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Seattle Children's).